<DOC>
	<DOCNO>NCT01389310</DOCNO>
	<brief_summary>The purpose study monitor adverse event HIV-infected child &lt; 18 year old expose Atazanavir real-world set Europe .</brief_summary>
	<brief_title>Post-marketing Safety Surveillance Program Human Immunodeficiency Virus ( HIV ) -Infected Children Exposed Atazanavir Europe</brief_title>
	<detailed_description />
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<mesh_term>Atazanavir Sulfate</mesh_term>
	<criteria>HIVinfected child participate individual prospective paediatric HIV cohort Receive Atazanavir treatment 01JAN2011 30DEC2013 Age &lt; 18 year old date start Atazanavircontaining regimen Have minimum 3 month followup</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>December 2014</verification_date>
</DOC>